The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months. Therapies are under development to improve outcomes and include targeting the eukaryotic translation initiation factor (eIF4E) with its inhibitor ribavirin. In a Phase II clinical trial in poor prognosis AML, ribavirin monotherapy yielded promising responses including remissions; however, all patients relapsed. Here we identify a novel form of drug resistance to ribavirin and Ara-C. We observe that the sonic hedgehog transcription factor glioma-associated protein 1 (GLI1) and the UDP glucuronosyltransferase (UGT1A) family of enzymes are elevated in resistant cells. UGT1As add glucuronic acid to many drugs, modifying their activity in diverse tissues. GLI1 alone is sufficient to drive UGT1A-dependent glucuronidation of ribavirin and Ara-C, and thus drug resistance. Resistance is overcome by genetic or pharmacological inhibition of GLI1, revealing a potential strategy to overcome drug resistance in some patients.

authors

  • Zahreddine, Hiba Ahmad
  • Culjkovic-Kraljacic, Biljana
  • Assouline, Sarit
  • Gendron, Patrick
  • Romeo, Andrea A
  • Morris, Stephen J
  • Cormack, Gregory
  • Jaquith, James B
  • Cerchietti, Leandro
  • Cocolakis, Eftihia
  • Amri, Abdellatif
  • Bergeron, Julie
  • Leber, Brian
  • Becker, Michael W
  • Pei, Shanshan
  • Jordan, Craig T
  • Miller, Wilson H
  • Borden, Katherine LB

publication date

  • July 2014